Market Research Logo

Lennox Gastaut Syndrome - Epidemiology Forecast to 2027

DelveInsight’s ‘Lennox Gastaut Syndrome - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Lennox Gastaut Syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Lennox Gastaut Syndrome Epidemiology

The Lennox Gastaut Syndrome epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Lennox Gastaut Syndrome are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
According to DelveInsight, the prevalent cases of Lennox Gastaut Syndrome was 68,562 in 2016 in 7 MM and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of Lennox Gastaut Syndrome with 31,772 prevalent cases in 2016 followed by Germany.

Lennox Gastaut Syndrome Epidemiology Segmentation

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
The disease epidemiology covered in the report is segmented by sex-specific [Male and Female] and seizure specific [Tonic, Myoclonic, Absence, Static, Partial].

Report Scope

• The report covers detailed overview of Lennox Gastaut Syndrome explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of Lennox Gastaut Syndrome
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by gender and sub-types in 7MM

Key strengths

• 10 Year Forecast of Lennox Gastaut Syndrome epidemiology
• 7MM Coverage
• Total Prevalent Cases of Lennox Gastaut Syndrome
• Prevalent Cases according to segmentation: Diagnosed prevalent cases, Gender-specific prevalence, seizure-type specific prevalence

Key assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population


1. Key Insights
2. Disease Overview: Lennox Gastaut Syndrome (LGS)
2.1. Introduction
2.2. Classification
2.3. Signs and Symptoms
2.4. Types of Seizures associated with LGS
2.5. Etiology
2.6. Pathogenesis
2.7. Diagnosis
2.7.1. Differential Diagnosis
3. Epidemiology and Patient Population
3.1. Key Findings
3.2. 7MM Total Diagnosed Prevalent Patient Population of Lennox Gastaut Syndrome (LGS)
3.3. Country Wise-Epidemiology of Lennox Gastaut Syndrome (LGS)
3.4. United States
3.4.1. Assumptions and Rationale
3.4.2. Diagnosed Prevalent Cases of Lennox Gastaut Syndrome in the United States
3.4.3. Gender-specific Diagnosed Prevalent Cases of LGS in the US
3.4.4. Seizure-specific Diagnosed Prevalent Cases of LGS in the US
3.5. Germany
3.5.1. Assumptions and Rationale
3.5.2. Diagnosed Prevalent Cases of LGS in Germany
3.5.3. Gender-specific Diagnosed Prevalent Cases of LGS in Germany
3.5.4. Seizure-specific Diagnosed Prevalent Cases of LGS in Germany
3.6. France
3.6.1. Assumptions and Rationale
3.6.2. Diagnosed Prevalent Cases of LGS in France
3.6.3. Gender-specific Diagnosed Prevalent Cases of LGS in France
3.6.4. Seizure-specific Diagnosed Prevalent Cases of LGS in France
3.7. Italy
3.7.1. Assumptions and Rationale
3.7.2. Diagnosed Prevalent Cases of LGS in Italy
3.7.3. Gender-specific Diagnosed Prevalent Cases of LGS in Italy
3.7.4. Seizure-specific Diagnosed Prevalent Cases of LGS in Italy
3.8. Spain
3.8.1. Assumptions and Rationale
3.8.2. Diagnosed Prevalent Cases of LGS in Spain
3.8.3. Gender-specific Diagnosed Prevalent Cases of LGS in Spain
3.8.4. Seizure-specific Diagnosed Prevalent Cases of LGS in Spain
3.9. United Kingdom
3.9.1. Assumptions and Rationale
3.9.2. Diagnosed Prevalent Cases of LGS in the United Kingdom
3.9.3. Gender-specific Diagnosed Prevalent Cases of LGS in the United Kingdom
3.9.4. Seizure-specific Diagnosed Prevalent Cases of LGS in the United Kingdom
3.10. Japan
3.10.1. Assumptions and Rationale
3.10.2. Diagnosed Prevalent Cases of LGS in Japan
3.10.3. Gender-specific Diagnosed Prevalent Cases of LGS in Japan
3.10.4. Seizure-specific Diagnosed Prevalent Cases of LGS in Japan
4. Appendix
4.1. Report Methodology
5. DelveInsight Capabilities
6. Disclaimer
7. About DelveInsight
List of Tables and Figures
Table 1: Diagnosed Prevalent Patient Population of LGS in 7MM (2016-2027)
Table 2: Diagnosed Prevalent Cases of LGS in the United States (2016-2027)
Table 3: Gender-specific Diagnosed Prevalent Cases of LGS in the United States (2016-2027)
Table 4: Seizure-specific Diagnosed Prevalent Cases of LGS in the United States (2016-2027)
Table 5: Diagnosed Prevalent Cases of LGS in Germany (2016-2027)
Table 6: Gender-specific Diagnosed Prevalent Cases of LGS in Germany (2016-2027)
Table 7: Seizure-specific Diagnosed Prevalent Cases of LGS in Germany (2016-2027)
Table 8: Diagnosed Prevalent Cases of LGS in France (2016-2027)
Table 9: Gender-specific Diagnosed Prevalent Cases of LGS in France (2016-2027)
Table 10: Seizure-specific Diagnosed Prevalent Cases of LGS in France (2016-2027)
Table 11: Diagnosed Prevalent Cases of LGS in Italy (2016-2027)
Table 12: Gender-specific Diagnosed Prevalent Cases of LGS in Italy (2016-2027)
Table 13: Seizure-specific Diagnosed Prevalent Cases of LGS in Italy (2016-2027)
Table 14: Diagnosed Prevalent Cases of LGS in Spain (2016-2027)
Table 15: Gender-specific Diagnosed Prevalent Cases of LGS in Spain (2016-2027)
Table 16: Seizure-specific Diagnosed Prevalent Cases of LGS in Spain (2016-2027)
Table 17: Diagnosed Prevalent Cases of LGS in the United Kingdom (2016-2027)
Table 18: Gender-specific Diagnosed Prevalent Cases of LGS in the United Kingdom (2016-2027)
Table 19: Seizure-specific Diagnosed Prevalent Cases of LGS in the United Kingdom (2016-2027)
Table 20: Diagnosed Prevalent Cases of LGS in Japan (2016-2027)
Table 21: Gender-specific Diagnosed Prevalent Cases of LGS in Japan (2016-2027)
Table 22: Seizure-specific Diagnosed Prevalent Cases of LGS in Japan (2016-2027)
Figure 1: Diagnosed Prevalent Patient Population of LGS in 7MM (2016-2027)
Figure 2: Diagnosed Prevalent Cases of LGS in the United States (2016-2027)
Figure 3: Gender-specific Diagnosed Prevalent Cases of LGS in the United States (2016-2027)
Figure 4: Seizure-specific Diagnosed Prevalent Cases of LGS in the United States (2016-2027)
Figure 5: Diagnosed Prevalent Cases of LGS in Germany (2016-2027)
Figure 6: Gender-specific Diagnosed Prevalent Cases of LGS in Germany (2016-2027)
Figure 7: Seizure-specific Diagnosed Prevalent Cases of LGS in Germany (2016-2027)
Figure 8: Diagnosed Prevalent Cases of LGS in France (2016-2027)
Figure 9: Gender-specific Diagnosed Prevalent Cases of LGS in France (2016-2027)
Figure 10: Seizure-specific Diagnosed Prevalent Cases of LGS in France (2016-2027)
Figure 11: Diagnosed Prevalent Cases of LGS in Italy (2016-2027)
Figure 12: Gender-specific Diagnosed Prevalent Cases of LGS in Italy (2016-2027)
Figure 13: Seizure-specific Diagnosed Prevalent Cases of LGS in Italy (2016-2027)
Figure 14: Diagnosed Prevalent Cases of LGS in Spain (2016-2027)
Figure 15: Gender-specific Diagnosed Prevalent Cases of LGS in Spain (2016-2027)
Figure 16: Seizure-specific Diagnosed Prevalent Cases of LGS in Spain (2016-2027)
Figure 17: Diagnosed Prevalent Cases of LGS in the United Kingdom (2016-2027)
Figure 18: Gender-specific Diagnosed Prevalent Cases of LGS in the United Kingdom (2016-2027)
Figure 19: Seizure-specific Diagnosed Prevalent Cases of LGS in the United Kingdom (2016-2027)
Figure 20: Diagnosed Prevalent Cases of LGS in Japan (2016-2027)
Figure 21: Gender-specific Diagnosed Prevalent Cases of LGS in Japan (2016-2027)
Figure 22: Seizure-specific Diagnosed Prevalent Cases of LGS in Japan (2016-2027)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report